Cargando…
Diagnostic Performance of Serum Biomarkers Fibroblast Growth Factor 21, Galectin-3 and Copeptin for Heart Failure with Preserved Ejection Fraction in a Sample of Patients with Type 2 Diabetes Mellitus
More than half of the patients with heart failure have preserved ejection fraction (HFpEF), however evidence shows a mortality rate comparable to those with reduced ejection fraction. The aim of this study was to evaluate whether FGF21, galectin-3 and copeptin can be used as biomarkers to identify H...
Autores principales: | Ianoș, Raluca D., Pop, Călin, Iancu, Mihaela, Rahaian, Rodica, Cozma, Angela, Procopciuc, Lucia M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8470703/ https://www.ncbi.nlm.nih.gov/pubmed/34573919 http://dx.doi.org/10.3390/diagnostics11091577 |
Ejemplares similares
-
Copeptin in patients with heart failure and preserved ejection fraction: a report from the prospective KaRen-study
por: Hage, Camilla, et al.
Publicado: (2015) -
Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction
por: de Boer, Rudolf A, et al.
Publicado: (2011) -
Diagnostic Value of Serum Concentration of Galectin-3 in Patients With Heart Failure With Preserved Ejection Fraction
por: Jiang, Jing, et al.
Publicado: (2022) -
Circulating Fibroblast Growth Factor 21 is Associated with Diastolic Dysfunction in Heart Failure Patients with Preserved Ejection Fraction
por: Chou, Ruey-Hsing, et al.
Publicado: (2016) -
Evaluation of Galectin-3 as a Novel Diagnostic Biomarker in Patients with Heart Failure with Preserved Ejection Fraction
por: Kanukurti, Jyothirmayi, et al.
Publicado: (2020)